Sarepta: Late-breaking oral on Elevidys 3-year data vs. external control; caregiver-reported outcomes through 2 years.

Pooled 7.5-year safety data across Sarepta's gene therapy portfolio.

Real-world exon-skipping survival data.

What Happened: FDA Commissioner Marty Makary confirmed that Vinay Prasad will leave his role as CBER Director at the end of April, returning to his academic position at UCSF.

The Context: While framed as the planned conclusion of a one-year sabbatical, the timing is notable. Prasad's tenure saw increased scrutiny of rare disease therapies, with at least five cell and gene therapy rejections that experts believe could have received approval under previous leadership (e.g., the uniQure Huntington's Phase 3 demand).

What It Means: The rare disease and gene therapy sectors may see a recalibration of CBER's posture, though it remains unclear whether recent stringent decisions will be revisited or have become permanent institutional policy.

What Happened: Servier announced a definitive agreement to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in cash, a 68% premium over the prior closing price. The deal is expected to close in Q2 2026.

Why It Matters: The acquisition centers on Ojemda (tovorafenib), the first and only FDA-approved type 2 RAF inhibitor for pediatric low-grade glioma (pLGG). Servier is building a "glioma franchise," pairing Ojemda with its existing IDH-mutant therapy Voranigo.

Executive Impact: This is the year's second-largest biotech acquisition (trailing Gilead/Arcellx). It reinforces premium valuations for genetically defined oncology assets with established commercial traction.

What Happened: Lonza entered a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of $3 billion (CHF 2.3B). Lonza will receive $2.2B upfront and retain a 40% stake.

Why It Matters: The transaction completes Lonza's strategic transformation into a pure-play CDMO focusing exclusively on Integrated Biologics, Advanced Synthesis, and Specialized Modalities.

What Happened: MiniMed Group, the Medtronic diabetes spinoff, raised $560 million in its IPO at $20 per share—well below the $25–$28 marketed range. Shares closed Friday down 8% from the IPO price at $18.49.

Why It Matters: The weak reception signals intense investor skepticism about standalone diabetes device companies amid the GLP-1 "halo effect" reshaping metabolic disease treatment.

What Happened: Sanofi agreed to sell its Medley generics unit to Brazil's EMS for more than $500 million.

Why It Matters: The sale continues Sanofi's "Play to Win" strategy of shedding non-core, low-margin assets to support its pivot toward innovative therapies following recent acquisitions of Vigil Neuroscience, Blueprint Medicines, and Dynavax.

Milestone: The FDA confirmed it will convene the Oncologic Drugs Advisory Committee (ODAC) on April 30 to review AZ's camizestrant (oral SERD) and a new indication for Truqap (capivasertib). This will be the first drug-related advisory committee meeting since July 2025, ending a nine-month hiatus.

Strategy: Announced a strategic push into the off-patent GLP-1 market in Canada and Brazil, positioning for long-term biosimilar opportunities as primary metabolic patents begin to expire globally.

Data: Reported that petrelintide achieved a 10.7% mean weight reduction at 42 weeks versus 1.7% for placebo in the ZUPREME-1 trial. While below GLP-1 benchmarks, the drug demonstrated placebo-like tolerability with no vomiting and no GI-related discontinuations at the maximally effective dose.

The Strategic Pivot: Zealand and partner Roche are positioning petrelintide as a "tolerability-first" alternative and a combination partner. A Phase 2 trial combining petrelintide with Roche's CT-388 (GLP-1/GIP dual agonist) will initiate in H1 2026.

Data: Presented smart knee data at AAOS showing patients with Persona IQ implants and the Mymobility platform had revision rates of 0.3% versus 1.0% for traditional implants at one year. Periprosthetic joint infection rates were also significantly lower.

Funding: Closed an oversubscribed financing round led by Morningside Ventures. Funds will support pivotal data readout, FDA submission, and the 2027 commercial launch of Spectris, a non-invasive neuromodulation device for Alzheimer's disease.

Milestone: Chugai Pharmaceutical confirmed the commercial launch of ELEVIDYS in Japan in late February, the country's first regenerative medical product for Duchenne muscular dystrophy. Sarepta is eligible for a $40 million milestone payment.

Strategy: Kicked off its presence at the Leerink Partners Global Healthcare Conference, highlighting its dual amylin/calcitonin receptor agonists as the definitive "third wave" of obesity treatment.

Enforcement: The FDA issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products. Commissioner Makary stated: "It's a new era. We are paying close attention to misleading claims being made... and taking swift action."

Impact: The agency's recent codification of "one pivotal trial plus confirmatory evidence" as the default approval standard continues to reshape development strategies. Small-cap biotechs with robust Phase 2 data are increasingly viewed as "NDA-ready," bypassing years of Phase 3 capital requirements.